Search Orphan Drug Designations and Approvals
-
Generic Name: | Atovaquone | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Mepron | ||||||||||||||||
Date Designated: | 09/10/1990 | ||||||||||||||||
Orphan Designation: | Treatment of AIDS associated Pneumocystis Carinii Pneumonia. | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park, North Carolina 27709 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Atovaquone |
---|---|---|
Trade Name: | Mepron | |
Marketing Approval Date: | 11/25/1992 | |
Approved Labeled Indication: | For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole. | |
Exclusivity End Date: | 11/25/1999 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-